Grifols has established a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to investigate ocular surface immunoglobulin (OSIG) eye drops aimed at treating ocular damage resulting from sulfur mustard exposure. BARDA, part of the U.S. Department of Health
Grifols Partnership is a contract development and manufacturer (CDMO) focused on added value injectable products, with international experience in the development and manufacturing of sterile drug products. Ahead of CDMO Live the following is an interview with Carla Moessinger, Business
Marga Viñes Senior Business Development Manager for Grifols contract manufacturing, explains the drug development and manufacturing services that they offer to customers.
Grifols Contract Manufacturing & Development (CDMO) Profile Grifols is a global healthcare company founded in Barcelona in 1909, dedicated to improving the health and well-being of people worldwide. Specializing in essential plasma-derived medicines and transfusion medicine, Grifols develops, produces, and
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
